Chemical hair straightener cancer lawsuits – access leading experts, medical chronologies, record reviews, and physician consultations.


Zantac’s History

Ranitidine was first developed in 1977 by the British pharmaceutical company, GlaxoSmithKline (GSK). In 1983, Zantac was approved by the FDA as a short-term ulcer treatment and became widely available in the U.S. By 1988, it was considered the world’s best-selling drug, with $1 billion in annual sales. By this time, Zantac was being used to treat more than just common ulcers. The drug was also a common treatment for heartburn and gastroesophageal reflux disease (GERD).

In 1997, GSK’s U.S. patent for Zantac expired. Competitors began manufacturing generic ranitidine drugs alongside the brand name, Zantac. In 2004, Pfizer developed the first non-prescription version of Zantac, which was made available over-the-counter (OTC). The Zantac brand was purchased from Pfizer first by Johnson & Johnson, then by Boehringer Ingelheim Pharmaceuticals, and then, most recently, by Sanofi SA. Generic over-the-counter versions were also released to the U.S. market. In 2018, Zantac was prescribed to over 25 million patients. The drug made $124 million in sales in the United States.


How Zantac Works

Zantac is commonly used to treat peptic ulcers, GERD, and heartburn. It works by effectively blocking histamine receptors in the stomach lining to decrease stomach acids. Ranitidine belongs to a class of antacid drugs called histamine-2 receptor agonists. These drugs work by preventing the production of stomach acid via an enzyme called the proton pump. Zantac starts relieving symptoms of heartburn and related conditions in about 30 minutes. The drug’s acid prevention benefits can last for up to 12 hours per dosage.


The Dangers of Zantac & NDMA

The dangers of Zantac and generic ranitidine drugs were first uncovered by Valisure, a Connecticut-based online pharmacy, in September 2019. The company informed the FDA that it found shocking levels of NDMA in the drug. The acceptable daily limit of NDMA is 96 nanograms, but Valisure found over 3,000,000 nanograms in every lot of ranitidine that it tested.

In response to this discovery, the FDA issued a statement warning that some ranitidine medications may contain NDMA. The FDA also recommended that manufacturers test their products via Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS). Manufacturers were also asked to send in samples for further examination. Following this announcement, ranitidine manufacturer, Sandoz, issued a voluntary recall for 14 lots of its prescription capsules. Walgreens, CVS Pharmacy, Rite-Aid, and Walmart also suspended all sales of Zantac and its generic counterparts.

Expert insights have never been more important.


The FDA’s Zantac Testing

On November 1, 2019, the FDA released its own test results. The agency concluded that the levels of NDMA in ranitidine were similar to the levels found in “common foods like grilled or smoked meats.” The tests were not done on humans. Rather, they were conducted using simulations of what would happen upon ranitidine’s exposure to acids in the stomach. The FDA concluded that ranitidine would not form NDMA in the intestines.

However, the FDA also found that some of the tested medications contained levels of NDMA that exceeded acceptable amounts and asked companies to issue voluntary recalls. By January 2020, 14 generic Zantac manufacturers had issued recalls in the United States. All 14 recalls followed the FDA’s advisory that drugmakers should test all ranitidine-containing products.


Zantac’s Recall

On April 1, 2020, the FDA requested that all manufacturers withdraw prescription and over-the-counter medications containing ranitidine from the market immediately. Unlike the previous testing that revealed no critical danger, the FDA had since determined that the amount of NDMA present in Zantac increased over time, especially when the drug was stored at high temperatures. This could result in unacceptable daily intake levels of NDMA. The announcement advised consumers to stop taking ranitidine medications or to speak with their health care providers about safe alternatives.

As a known human carcinogen, NDMA is naturally present in some foods and in water. At low levels, it is not expected to increase one’s risk of cancer. However, the NDMA levels observed in ranitidine products presented clear cancer risks. The FDA also determined that the “inherent instability” of the ranitidine molecule supports NDMA formation both within the medication and within the human body upon digestion.


Ongoing Zantac Class Actions

In September 2019, the first class action lawsuit against Zantac manufacturers, Sanofi and Boehringer Ingelheim, was filed in the Northern District Court of California. The four plaintiffs alleged that the defendants failed to warn consumers of the dangers associated with the medication. The complaint further alleges Zantac’s inherent design defect—that the drug reacts within the human body, creating potentially harmful amounts of NDMA.

A second lawsuit was filed in the District Court of New Jersey just a week later, echoing the initial allegations. By February 2020, more than 140 similar lawsuits were filed against Zantac manufacturers in federal courts. This resulted in consolidation by the Judicial Panel for Multidistrict Litigation to the Southern District of Florida. The transfer order also includes actions brought individually by plaintiffs. As of May 2020, the consolidation captured 230 lawsuits. This number is only expected to grow.


Expert Witnesses for Zantac Litigation

As in any product liability case, medical experts will be critical in the outcome of these class actions. Oncologists, particularly those who specialize in the affected areas, such as gastrointestinal oncologists, will undoubtedly be needed to establish the plaintiffs’ cancer diagnoses.

Perhaps even more importantly, a link between the injury and the medication must be demonstrated. The higher and more frequent the dose, the greater likelihood that the plaintiff developed cancer from the medication. It is important to remember that the FDA approves NDMA exposure within a certain limit. As such, plaintiffs must prove that Zantac, and other ranitidine medications, exceeded the recommended daily intake of NDMA.

Establishing the Zantac-cancer connection will likely require the expertise of toxicologists who are versed in the carcinogenic effect of NDMA on the human body. For example, the International Agency for Research on Cancer (IARC) lists NDMA as a chemical probably carcinogenic to humans, while the U.S. National Toxicology Program “reasonably anticipated” it to be a human carcinogen. In fact, the National Toxicology Program uses NDMA in laboratory settings to induce cancer in rats. Such testing can prove useful during a trial in proving NDMA’s effects on humans.

Expert E-000083

Hematology and Oncology Expert

This supremely qualified hematologist/oncologist has remained in active practice for over 30 years and has acquired such high ranking clinical appointments as the Chief of Hematology/Oncology at several prior institutions. He also currently holds a clinical professorship in his field, is an attending physician, as well as a reviewer for major hematology and oncology editorials....

Expert E-000316

Toxicology Expert

This expert has over 30 years of experience working in the toxicology and health risk assessment field. He specializes in evaluating potential human health effects of chemical and microbial agent exposures. In particular, he has experience with evaluation of exposures to asbestos, benzene, carbon monoxide, silica, metals, pesticides, solvents, oil and gas fracking chemicals, other petroleum products, and toxic gases. Additionally, he is a Board-Certified Toxicologist as ...

Expert E-000988

Family Medicine and Primary Care Expert

This board certified expert has been practicing for nearly 20 years. He completed his residency in Family Practice at the University of California, San Francisco prior to completing a fellowship as a Robert Wood Johnson Clinical Scholar, a highly selective postresidency program where physicians learn to conduct innovative research and work with communities, organizations, practitioners, and policy makers on issues important to the health and well-being of all Americans. ...

Expert E-001445

Toxicology Expert

This expert holds a doctorate degree in toxicology and has been a practicing toxicologist for over 40 years. Board certified by the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences, he had published over 35 scientific articles and is a former president of the Mid-Atlantic chapter of the Society of Toxicology. He spent over 30 years as a Director of Toxicology for two major pharmaceutical companies and currently serves as an independent ...

Expert E-004473

Dermatology and Mohs Micrographic Surgery Expert

This expert is board certified in dermatology and completed fellowship training in dermatologic surgery/mohs micrographic surgery at the University of Iowa Hospitals and Clinics. He is a member of the Association of Academic Dermatologic Surgeons and has authored more than 40 peer reviewed dermatology publications. He is current a professor of dermatologic surgery and cutaneous laser surgery at a major medical institution....

Expert E-006778

Radiation Oncology Expert

This expert is trained and board certified in radiation oncology. Currently a professor at a major medical center, he continues to treat patients and conduct research projects. He also serves as a reviewer for the International Journal of Gynecological Cancer and the Journal of Clinical Oncology. His clinical interests include pediatric cancers, breast cancer and sarcoma....

Expert E-007680

Hematology and Oncology Expert

This expert has over 13 years of experience as a Physician Assistant. His expertise consists of Bone Marrow Transplant, Hematology/Oncology, Infusion Medicine, Emergency Medicine, and Urgent Care. He currently serves as a Physician Assistant for the Bone Marrow Transplant team at a major university medical center....

Expert E-008870

Radiation Oncology Expert

This highly qualified, board certified Professor of Radiation Oncology received his medical degree from the University of Virginia. He subsequently completed a Residency in Radiation Oncology and Fellowship training in Clinical Oncology. He is a member of numerous professional societies including the American Society of Therapeutic Radiology and Oncology. This expert has recieved many awards throughout his career including the Ulrich Henschke Award. This expert has ...